Xeris is a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use, liquid-stable injectables. The company’s proprietary XeriSol™ and XeriJect™ formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of highly concentrated, non-aqueous, ready-to-use formulations of peptides, proteins, antibodies and small molecules using syringes, auto-injectors, multi-dose pens and infusion pumps. Xeris’ platforms have the potential to offer distinct advantages over existing formulations of marketed and development-stage products. In particular, XeriSol™ and XeriJect™ offer the opportunity to eliminate reconstitution, enable long-term room temperature stability, significantly reduce injection volume, and eliminate the requirement for intravenous (IV) infusion. These attributes can lead to products that are easier to use by patients, caregivers, and health practitioners and reduce costs for payers and the healthcare system.

from http://www.xerispharma.com/#!company/aboutPage

Research Grants 16 show all


$451.7K
2014

$1.5M
2015

$1.6M
2016

$1.9M
2017

$793.8K
2018

Patents 114show all

  • 23
    A61K - Preparations for medical, dental, or toilet purposes
  • 7
    A61M - Devices for introducing media into, or onto, the body
  • 4
    A61P - Specific therapeutic activity of chemical compounds or medicinal preparations

Clinical Trials 20show all

12Phase 26Phase 31Phase 11Phase 1/Phase 2

SEC Filings show all


23
8-K

8
D

6
10-Q

2
10-K

1
S-1

Contact Information

180 N LaSalle St. Suite 1810
Chicago, IL 60601
United States

Overview

Total FundingEmployeesLast Funding DateStatus
$232,700,000101-2502019-09-10Ipo

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2019-09-10$85,000,000Post Ipo DebtSilicon Valley Bank, Oxford Finance LLC
2018-03-08$45,000,000Debt FinancingSilicon Valley Bank, Oxford Finance LLC
2018-03-08$10,000,000Series CMerieux DeveloppementWild Basin Investments
2011-12-12$1,500,000Series ACentral Texas Angel Network
2017-05-19$30,000,000Series CMerieux DeveloppementWild Basin Investments
2015-01-07$4,900,000Debt Financing
2013-07-11$2,300,000Debt Financing
2010-12-20Non Equity AssistanceTexas Venture Labs
2015-01-07$13,000,000Series B
2016-01-07$41,000,000Series CRedmile GroupMcNair Group, Sabby Management, Deerfield

SEC Form D Funding Events

DateOfferedSoldType
2014-09-29$14,874,990$7,274,592Equity
2013-07-10$3,000,000$2,315,000Debt, Security to be Acquired
2013-02-14$3,000,000$1,750,000Debt, Security to be Acquired
2012-09-25$3,000,000$1,125,000Debt, Security to be Acquired
2011-10-12$1,958,748$1,837,848Equity, Option to Acquire, Security to be Acquired
2005-11-29Unknown Unknown Other (Paper Filing)

Key Executives

  • Yash Sabharwal
    Executive Officer
  • John Kinzel
    Executive Officer, Director
  • Doug Baum
    Director
  • Steven Prestrelski
    Executive Officer, Director
  • John Kinzell
    Executive Officer, Director
  • Douglas Baum
    Director
  • Timothy Sullivan
    Director
  • Shane Brisbin
    Director